Nurix Therapeutics, Inc. (NRIX) Q1 2025 Earnings
NRIX·Reported April 8, 2025·Before market open
Nurix Therapeutics, Inc. reported Q1 2025 revenue of $18.5M, beat analyst consensus of $15.8M by $2.6M. Diluted EPS came in at $-0.67, beat the $-0.72 consensus by $0.05.
Revenue
$18.5Mbeat by $2.6M
Consensus: $15.8MDiluted EPS
$-0.67beat by $0.05
Consensus: $-0.72
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Nurix Therapeutics, Inc.'s Q1 2025 earnings report.
Nurix Therapeutics, Inc. (NRIX) reported Q1 2025 earnings on April 8, 2025 before market open.
Nurix Therapeutics, Inc. reported revenue of $18.5M and diluted EPS of $-0.67 for Q1 2025.
Revenue beat the consensus estimate of $15.8M by $2.6M. EPS beat the consensus estimate of $-0.72 by $0.05.
You can read the 10-Q periodic report (0001549595-25-000055) directly on SEC EDGAR. The filing index links above go to sec.gov.